Home
Leadership
Technology
Product
Market
Investors
Publications
Contact
Menu
Home
Leadership
Technology
Product
Market
Investors
Publications
Contact
Investment
Investment Highlights
LC101 development was completed and led by the inventor of the branded Doxil®
Signed strategic agreement with tier 1 pharma company to commercialize LC101 in the U.S. market
Obtained FDA US marketing authorisation for LC101
FDA accredited, cGMP manufacturing facility secured to support commercial launch
Overall $500m ww market opportunity with very few competitors due to high entry barriers
(i.e. complex nano-drug)
Upcoming Catalysts
LC101 obtained FDA US marketing authorisation
Further international expansion (e.g. China) of LC101 via on-going BD efforts
Pipeline of Liposomal products based on Ayana’s platform technology are in development
error:
Content is protected !!